RGEN REPLIGEN CORP
FollowStock (common), issuer CIK 730272
Filings received so far for Q3 2026: 16 13F filers report a position in RGEN shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.
13D and 13G filers
Each filer's latest stake. The shares are the aggregate the reporting persons state, which can include entities that file no 13F.
- FMR LLC(group FMR LLC)
7,361,318 shares, 13% in a 13G/A as of 2026-09-30,0000315066-26-002329
Accepted , ingested
Insider trades
| Owner | Date | Shares | Price | Filing |
|---|---|---|---|---|
| Douglass Brian Robbofficer (CHIEF PRODUCT OFFICER) | 2026-10-06 | +700 A | $0 | Form 4 |
| Loeillot Olivierdirector, officer (Chief Executive Officer) | 2026-10-05 | -4,202 S | $190 | Form 4 |
| Loeillot Olivierdirector, officer (Chief Executive Officer) | 2026-10-05 | +4,202 M | $154.96 | Form 4 |
| Loeillot Olivierdirector, officer (Chief Executive Officer) | 2026-10-05 | -1,333 S | $178.75 | Form 4 |
13F holders, Q3 2026
Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.
Events
Douglass Brian Robb acquired 700 RGEN shares on 2026-10-06, Form 4 filed 2026-10-08. 0001628280-26-065462
Accepted , ingestedFMR LLC and 1 other reporting person reported 7,361,318 RGEN shares, 13% of the class, as of 2026-09-30, in a 13G/A filed 2026-10-07. 0000315066-26-002329
Accepted , ingestedLoeillot Olivier disposed of 1,333 RGEN shares on 2026-10-05, Form 4 filed 2026-10-06. 0001628280-26-065238
Accepted , ingested